Work

Randomized, Double-blind, Placebo Controlled Phase 1 Study of Ath-063: a Novel, Oral, Artificial Intelligence-generated Drug for Inflammatory Bowel Disease

Year: 2026

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Inflammatory Bowel Diseases

DOI: 10.1093/ibd/izag006.022

Authors: Allan Pantuck, Iordanis Karagiannidis, David Ho, Phithi Nguyen, Nalin Singh, Georgios Dialynas, Maria-Malvina Tsamouri, Riccardo Calandrelli, Dimitrios Iliopoulos

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7125416825

FWCI:

Cites:

Cited by:

Related to: